The new global scenario in times of COVID-19 makes it necessary to take urgent measures and assess the impacts they will have. ECLAC has built this Observatory to support review and follow-up over the medium and long terms and at the request of CELAC. The Observatory tracks the public policies that ...the 33 countries of the Latin America and Caribbean region are implementing to limit the impact of the COVID-19 pandemic, and offers analyses of the economic and social impacts that these policies will have at the national and sectoral levels.
more
Version 2.3 , 21 April 2022. The CVIC tool supports credible COVID-19 vaccination costing to facilitate a dialogue with stakeholders, while maintaining sensitivity to protect essential health services.
The CVIC tool provides a structured and comprehensive estimation of incremental operational and... selected capital costs of introducing and deploying COVID-19 vaccines, in alignment with the National Deployment and Vaccination Plan (NDVP). This is essential for resource mobilization, budgeting, and delivery strategy refinement and optimization. The tool has been pre-populated with data from global databases and provides a total cost estimate over an immunization programme over the period of 2021-2023, after which COVID-19 vaccination is expected to be integrated into national immunization plans. Countries can customize the priority target populations based on WHO SAGE guidance and select multiple delivery strategies and vaccine products. The tool is available in all six UN working languages (Arabic, Chinese, English, French, Russian and Spanish) and Portuguese. An e-learning course on CVIC is available at OpenWHO.
In this updated version 2.3 of the tool, some minor bugs have been fixed and new features have been added
more
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
Ethnic disparities in COVID-19 persist, with increased rates of infection, severe disease, and death among people from minority ethnic groups. COVID-19 vaccination rates also remain lowest in these communities compared with white people in the UK. Among people older than 18 years, the proportion who... have had three COVID-19 vaccinations in England in March, 2022, was lowest among Black Caribbean (38%), Black African (45%), and Pakistani (45%) ethnic groups. These disparities are likely to be attributed to the intersection of key social determinants, including socioeconomic factors such as deprivation, overcrowding, and working patterns and conditions,
alongside discrimination and structural violence in the health-care system and society.
more
an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, latest update: 21 January 2022
Available in English, F...rench, Spanish
more
To access a video in all available languages, click its picture in the library.
Here you can download videos in different local languages to communicate and educate in the community
In dieser Fokuserhebung wurde die deutschsprachige Erhebung durch Interviews in weiteren fünf Sprachen ergänzt. Damit wurden in dieser Erhebung auch Personengruppen erreicht, die in vorherigen Erhebungen aufgrund einer Sprachbarriere nicht erreicht werden konnten. Insgesamt liefert diese Befragung... daher Ergebnisse, die die Bevölkerung in Deutschland besser abbilden können.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th...is document has been updated: Version 6 June 2022.
more
Die Infografik "Infektionen vorbeugen: Die 10 wichtigsten Hygienetipps" gibt einen Überblick über einfache persönliche Hygienemaßnahmen, um sich und andere vor ansteckenden Infektionskrankheiten zu schützen.
This research report offers community perceptions of COVID-19 from migrants, refugees, host communities and indigenous populations in nine countries in the Americas: Argentina, Brazil, Bolivia, Colombia, Guatemala, Nicaragua, Jamaica, Panama and Trinidad and Tobago.
It reveals the myriad impacts ...that COVID-19 has had, and continues to have, on vulnerable and hard-to-reach populations. And it offers hands-on recommendations around the impact and usefulness of health information; trust, awareness and access to vaccines; and the socio-economic impact of the pandemic.
more
Global Fund Strategy 2023-2028
Available in different languages from the website https://www.theglobalfund.org/en/publications/
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets.
more
5 April 2022, Addendum. This policy brief confirms WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from COVID-19 immunization campaigns. It also calls attention to information on specialized syringes for COVID-19 vaccines and br...oad short-term and long-term solutions to address and alleviate supply shortages related to vaccine products with non-standard dose volumes.
more
Seit August 2021 empfiehlt die Ständige Impfkommission (STIKO) allen Kindern und Jugendlichen ab 12 Jahren die Corona-Schutzimpfung mit Comirnaty® von BioNTech/Pfizer. Seit Mitte Dezember können auch Kinder zwischen 5 und 11 Jahren mit dem darauf angepassten Impfstoff von BioNTech/Pfizer geimpft ...werden. Hier finden Sie alles zur Zulassung und der STIKO-Empfehlung sowie kindgerechte Dokumente und Hintergrundinformationen für den Alltag mit Kindern in der Pandemie.
more